logo-loader
viewReNeuron Group PLC

ReNeuron makes key business development hire as it looks to build on licensing deals

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott following the news this morning that they've appointed a business development director, Nick Adams,  to help them build on the licence deals signed with Chinese giant Fosun Pharma.

Hunt also discusses the recent release of their preliminary results covering the 12 months to the end of March 2019.

One of the year's highlights came in February, when they reported positive initial data from the mid-stage study of its retinitis pigmentosa treatment.

Quick facts: ReNeuron Group PLC

Price: 121.5 GBX

LSE:RENE
Market: LSE
Market Cap: £38.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: ReNeuron in active on-going talks for further potential...

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the release of its interim results to September 2019. The biotech firm says it's in ongoing discussions with “commercial third parties” interested in out-licence deals across all its...

4 days, 18 hours ago

2 min read